Medtide, Inc. Class H
HHKEX:388019.35
HKD
-0.40
(-2.03%)
ISIN
CNE100006S86
Return %
Stock
S&P 500
1Y
-36.76
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
CNY
•
in mil. unless spec.Working Capital
CNY
•
in mil. unless spec.Growth Rates
CNY
•
in mil. unless spec.Semi-annual Revenue
CNY
•
in mil. unless spec.Semi-annual Earnings Per Share
CNY
•
in mil. unless spec.Semi-annual Dividends Per Share
CNY
•
in mil. unless spec.Company Description
- CEO
- Qi Xu
- Full Time Employees
- 566
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- No. 69, 12 Street Hangzhou ZH China 310018
- IPO Date
- Jun 30, 2025
- Website
- medtideinc.com
- Similar Companies
- Business
- Medtide Inc. (3880.HK) is a China-based contract research, development, and manufacturing organization (CRDMO) specializing in peptides; it offers full-cycle services from early-stage discovery and preclinical research to clinical development and commercial-stage production. The company provides contract research organization (CRO) services, including peptide new chemical entity (NCE) discovery synthesis, and contract development and manufacturing organization (CDMO) services, encompassing peptide chemistry, manufacturing, and controls (CMC) development, commercial manufacturing, and CMC filing support; its research platforms include OmniPeptSynth, PeptiConjuX, PeptiNuclide LinkTech, GreenSynth Innovations, and Impurity Screening, with a focus on complex molecules such as oral and/or injectable glucagon-like peptide-1 (GLP-1) products and active pharmaceutical ingredients (APIs). Incorporated in 2020 and headquartered in Hangzhou, China, Medtide operates commercial production bases and offices in China and the United States, serving over 1,000 customers worldwide across more than 50 countries, including major markets in North America, Europe, Japan, South Korea, Australia, and Asia; its client base spans large pharmaceutical and biotech firms as well as biotech startups and virtual pharmaceutical companies. In a key recent development, the company, formerly known as Taide Pharmaceutical (Zhejiang) Co., Ltd., changed its name to Medtide Inc. in February 2023 and successfully completed an initial public offering raising HK$411.2 million, listing on the Hong Kong Stock Exchange in June 2025 under stock code 03380.HK, marking a significant milestone in its global expansion.